Steve Colletti, Ph.D., chief scientific officer at Korro Bio, brings nearly 30 years of drug discovery and development experience covering a broad range of therapeutic areas and modalities.
Steve was previously SVP of Drug Discovery R&D at Zymergen (acquired by Ginkgo Bioworks in 2022) and CSO at Lodo Therapeutics (acquired by Zymergen in 2021). He has nearly 25 years of experience from multiple roles at Merck, with leadership in small molecule, natural products, oligonucleotide, peptide and fusion protein bioconjugate drug discovery, targeting programs in cardiovascular and respiratory disease, diabetes and obesity, immunological disorders, infectious diseases, neuroscience and oncology. Dr. Colletti built and led the RNA Therapeutics Medicinal Chemistry department and was a core member of multiple development teams that were responsible for discovering more than a dozen preclinical candidates and advancing them to clinical development. His duties also included working closely with licensing and business development, evaluating external opportunities and helping to manage acquisitions. Dr. Colletti is an inventor and author of over 130 patents and publications.
Steve received his Ph.D. in chemistry from Boston University and was a National Institutes of Health postdoctoral fellow in chemistry at the Scripps Research Institute.